COVID-19 Vaccines Appear to Have a Big Added Bonus
A health care worker prepares a shot of the Pfizer COVID-19 vaccine in La Paz, Bolivia, on Jan. 7. (AP Photo/Juan Karita, file)
A surprising new study suggests that the Pfizer and Moderna COVID-19 vaccines may offer an unexpected benefit for some cancer patients — helping their immune systems fight tumors more effectively.
Researchers from the University of Florida and the MD Anderson Cancer Center in Houston found that people with advanced lung or skin cancer lived significantly longer if they received an mRNA COVID-19 vaccine within 100 days of beginning certain immunotherapy treatments. The findings were published Wednesday in the journal Nature.
Importantly, the benefit appeared unrelated to COVID-19 itself. Instead, scientists say the mRNA molecule at the core of these vaccines seems to strengthen the immune system’s response to modern cancer drugs known as checkpoint inhibitors.
“The vaccine acts like a siren to activate immune cells throughout the body,” explained Dr. Adam Grippin of MD Anderson, the study’s lead researcher. “We’re sensitizing immune-resistant tumors to immune therapy.”
The team found the results so promising that they’re now planning a larger, more controlled clinical trial to test whether pairing mRNA vaccines with checkpoint inhibitors could become a new standard approach — while also developing experimental mRNA vaccines specifically designed to target cancer cells.
Dr. Grippin and his colleagues first made the connection while studying custom mRNA cancer vaccines. They noticed that even general-purpose mRNA vaccines — those without specific tumor targets — appeared to stimulate similar immune activity. That led them to investigate whether the already widespread Pfizer and Moderna COVID shots might provide the same boost.
Reviewing medical records from nearly 1,000 advanced cancer patients treated at MD Anderson, the researchers discovered that those who received an mRNA vaccine lived noticeably longer than those who did not. Vaccinated lung cancer patients were almost twice as likely to be alive three years after starting treatment, while melanoma patients also showed substantially longer survival rates.
By contrast, traditional non-mRNA vaccines, such as flu shots, showed no measurable impact on outcomes.
While early, the research opens the door to a new and potentially powerful partnership between mRNA vaccine technology and cancer immunotherapy — a development that could transform treatment strategies for some of the most challenging cancers.
About Post Author
